ASCENT-04/KEYNOTE-D19: Phase III study of sacituzumab govitecan (SG) plus pembrolizumab (pembro) vs treatment of physician's choice (TPC) plus pembro in first-line (1L) programmed death-ligand 1-positive (PD-L1+) metastatic triple-negative breast cancer (mTNBC)

被引：9
|
作者：
Tolaney, S. M. [1 ]
De Azambuja, E. [2 ]
Emens, L. A. [3 ]
Loi, S. [4 ]
Pan, W. [5 ]
Huang, J. [6 ]
Sun, S. W. [6 ]
Lai, C. [6 ]
Schmid, P. [7 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA USA
[2] Jules Bordet Inst, Brussels, Belgium
[3] Univ Pittsburg, Med Ctr, Pittsburgh, PA USA
[4] Peter Maccallum Canc Ctr, Div Canc Res, Melbourne, Vic, Australia
[5] Merck & Corp Inc, Rahway, NJ USA
[6] Gilead Sci Inc, Foster City, CA USA
[7] St Bartholomews Hosp, London, England
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.1860
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
276TiP
引用
收藏
页码：S664 / S665
页数：2
相关论文
共 23 条
  • [1] ASCENT-04/KEYNOTE-D19: Phase 3 study of sacituzumab govitecan (SG) plus pembrolizumab (pembro) vs treatment of physician's choice (TPC) plus pembro in 1L programmed death-ligand 1-positive (PDL1+) metastatic triple-negative breast cancer (mTNBC)
    Huober, J.
    Tolaney, S. M.
    De Azambuja, E.
    Emens, L. A.
    Pan, W.
    Huang, J.
    Sun, S. W.
    Schmid, P.
    SWISS MEDICAL WEEKLY, 2022, 152 : 66S - 67S
  • [2] ASCENT-03: Phase III study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in first-line (1L) metastatic triple-negative breast cancer (mTNBC)
    Bardia, A.
    Punie, K.
    Barrios, C. H.
    Schneeweiss, A.
    Zhai, X.
    Huynh, D. H.
    Vaksman, N.
    Lai, C.
    Tolaney, S. M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S663 - S664
  • [3] ASCENT-03: Phase 3 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in first-line (1L) metastatic triple-negative breast cancer (mTNBC)
    Huober, J.
    Bardia, A.
    Punie, K.
    Barrios, C.
    Schneeweiss, A.
    Zhai, S.
    Huynh, D.
    Vaksman, N.
    Lai, C.
    Tolaney, S. M.
    SWISS MEDICAL WEEKLY, 2022, 152 : 44S - 45S
  • [4] ASCENT: A randomized phase III study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC)
    Bardia, A.
    Tolaney, S. M.
    Loirat, D.
    Punie, K.
    Oliveira, M.
    Rugo, H. S.
    Brufsky, A.
    Kalinsky, K.
    Cortes, J.
    O'Shaughnessy, J.
    Dieras, V. C.
    Carey, L. A.
    Gianni, L.
    Piccart, M.
    Loibl, S.
    Goldenberg, D.
    Hong, Q.
    Olivo, M. S.
    Itri, L. M.
    Hurvitz, S. A.
    ANNALS OF ONCOLOGY, 2020, 31 : S1149 - S1150
  • [5] Sacituzumab govitecan (SG) plus pembrolizumab (pembro) in first-line (1L) metastatic non-small cell lung cancer (mNSCLC) with PD-L1 ≥ 50%: Cohort A of EVOKE-02
    Patel, Jyoti D.
    Cho, Byoung Chul
    Cobo, Manuel
    Cabanillas, Roxana Reyes
    Vicente, David
    Pradera, Jose Fuentes
    Garon, Edward B.
    Mok, Tony S. K.
    Cappuzzo, Federico
    Neal, Joel W.
    Mekan, Sabeen Fatima
    Safavi, Farnoush
    Fernando, Nelumka
    Chisamore, Michael Jon
    Reck, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] Saci-IO TNBC: Randomized phase II trial of sacituzumab govitecan (SG) plus /- pembrolizumab in PD-L1-metastatic triple-negative breast cancer (mTNBC).
    Garrido-Castro, Ana Christina
    Keenan, Tanya Elizabeth
    Li, Tianyu
    Lange, Paulina
    Callahan, Catherine
    Guerriero, Jennifer
    Tayob, Nabihah
    Anderson, Leilani
    Yam, Clinton
    Daniel, Brooke R.
    Carey, Lisa A.
    Nanda, Rita
    Winer, Eric P.
    Mittendorf, Elizabeth A.
    Tolaney, Sara M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] First-line (1L) maintenance therapy with niraparib (nira) plus pembrolizumab (pembro) vs placebo plus pembro in advanced/metastatic non-small cell lung cancer (NSCLC): Phase III ZEAL-1L study
    Ramalingam, S. S.
    de Castro, G., Jr.
    Garassino, M. C. C.
    Mazieres, J.
    Sanborn, R. E.
    Smit, E. F. F.
    Spigel, D. R.
    Thomas, M.
    Velcheti, V.
    Zhi, E.
    Whipple Neibauer, M.
    Stojadinovic, A.
    Peters, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S1030 - S1032
  • [8] First-line (1L) maintenance therapy with niraparib (nira) plus pembrolizumab (pembro) vs placebo plus pembro in advanced/metastatic non-small cell lung cancer (NSCLC): Phase 3 ZEAL-1L study
    Nagrial, Adnan
    Ramalingam, Suresh S.
    de Castro, Gilberto, Jr.
    Garassino, Marina Chiara
    Mazieres, Julien
    Sanborn, Rachel
    Smit, Egbert
    Spigel, David R.
    Thomas, Michael
    Velcheti, Vamsidhar
    Shi, Lei
    Neibauer, Melissa Whipple
    Stojadinovic, Alexander
    Peters, Solange
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 204 - 205
  • [9] Cost-effectiveness of pembrolizumab plus chemotherapy as first-line treatment in PD-L1-positive metastatic triple-negative breast cancer
    Huang, Min
    Fasching, Peter
    Haiderali, Amin
    Pan, Wilbur
    Gray, Emma
    Zhou, Zheng-Yi
    Hu, Peter
    Chaudhuri, Mitashri
    De Tilleghem, Celine Le Bailly
    Cappoen, Nicolas
    O'Shaughnessy, Joyce
    IMMUNOTHERAPY, 2022, 14 (13) : 1027 - 1041
  • [10] KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) plus olaparib (ola) vs pembro plus chemotherapy after induction with first-line (1L) pembro + chemo in patients (pts) with locally recurrent inoperable or metastatic TNBC
    Saji, S.
    Cussac, A. Llombart
    Andre, F.
    Robson, M. E.
    Harbeck, N.
    Schmid, P.
    Cescon, D. W.
    Ahn, J. S.
    Nanda, R.
    Fan, L.
    Mejia, J. A.
    Karantza, V.
    Bardia, A.
    Rugo, H. S.
    ANNALS OF ONCOLOGY, 2020, 31 : S1268 - S1268
123